Browse > Home / FDA News / FDA Alerts Public to Liver Injury Reports in Xenical, Alli Patients

FDA Alerts Public to Liver Injury Reports in Xenical, Alli Patients

August 26, 2009

FDA Alerts Public to Liver Injury Reports in Xenical, Alli Patients
The FDA is reviewing adverse event reports of serious liver loss in patients taking couple weight-loss drugs — Roche’s usage method of treating Xenical and GlaxoSmithKline’s (GSK) OTC drug Alli. The FDA has believed 32 reports of serious liver injury from 1999 to 2008, but nay definite association between liver harm and Xenical (orlistat) or Alli (orlistat) has been established, according to a statement on its website. Twenty-seven of the patients required hospitalization and six suffered liver failure. All but two of the incidents occurred outside the U.S.

Written by Samanta · Filed Under FDA News